Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Cancer treatments Stories

2013-12-14 23:03:17

In response to an article published by Yotta Fire, Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on a study that looks into a new and effective method of delivering chemotherapy drugs directly to brain cancer patients. New York, NY (PRWEB) December 14, 2013 Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, responds to an article published by Yotta Fire on December 4th that discusses a new...

2013-12-14 08:20:06

Fourth Head-to-Head Comparison Reveals Important Clinical Distinctions Between Oncotype DX, the Only Test Demonstrated to Predict Chemotherapy Benefit, and Tests Limited to Breast Cancer Prognosis REDWOOD CITY, Calif., Dec. 14, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from three studies of its Oncotype DX(®) breast cancer test presented at the 36(th) Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), reinforcing the unmatched value of the...

2013-12-13 08:24:48

VENTANA HER2 (4B5) IHC assay label expansion coincides with therapy availability in many non-U.S. countries globally TUCSON, Ariz., Dec. 13, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announces the VENTANA HER2/neu (4B5) Rabbit Monoclonal Primary Antibody assay as a companion diagnostic(1) for detecting HER2 protein expression for patients who, in countries where they are approved, may be appropriate candidates for Perjeta(®) (pertuzumab)...

2013-12-12 10:58:07

In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment, investigators at Dana-Farber Cancer Institute and other research centers will report at the 2013 San Antonio Breast Cancer Symposium. The findings offer, for the first time, a set of standard treatment guidelines for...

2013-12-11 12:07:24

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. "Worldwide, anthracyclines such as doxorubicin [Adriamycin] and epirubicin have...

2013-12-11 12:05:10

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. "We have previously shown that high levels of tumor-infiltrating lymphocytes [immune cells in a tumor] are predictive of response to trastuzumab and chemotherapy administered after surgery for early-stage,...

2013-12-11 12:02:49

Results from the initial analysis of event-free and overall survival for patients enrolled in the randomized, phase III Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO) trial are to be presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10–14. "NeoALTTO is a randomized, phase III clinical trial evaluating whether a combination of two HER2-targeted therapies, trastuzumab and lapatinib, given with standard paclitaxel chemotherapy before...

Engineered Immune Cells Fight Cancer
2013-12-09 14:30:13

Brett Smith for redOrbit.com - Your Universe Online Researchers from the University of Pennsylvania and the Children’s Hospital of Philadelphia have been able to reprogram the body’s immune system to fight leukemia, with 89 percent of children and adults in a series of clinical trials showing no evidence of cancer after receiving a personalized cell therapy. The findings from the first 59 patients to receive this cutting-edge therapy, known as CTL019, were presented during the...

2013-12-09 12:25:21

UTRECHT, The Netherlands, December 9, 2013 /PRNewswire/ -- Dutch couple invents improved cooling cap to support more cancer patients An improved scalp cooling cap worn during chemotherapy can help those with cancer avoid hair loss during their treatment. The new ChemoHairSaver has been developed by Dutch couple Arie and Caroline van Wijngaarden after Caroline was herself treated for breast cancer. Their patented invention is applauded by oncologists, hospitals,...

2013-12-07 08:20:35

--Researchers at The Children's Hospital of Philadelphia and the University of Pennsylvania Harness Engineered T Cells to Eliminate Tumors in Blood-- NEW ORLEANS, Dec. 7, 2013 /PRNewswire/ -- Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient's immune system. In pilot studies of bioengineered T cells that attack leukemia,...